-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"We envision that our inhibitory drugs acting on the same protein will one day play the same role in these mice, Alzheimer's disease, and statins in heart disease, helping to stop the disease from progressing," said Joachim Hertz, MD, Molecular Genetics , Professor of Neurology and Neuroscience UTSW
Almost 6 million Americans suffer from Alzheimer's disease, and most of them develop late-onset dementia after the age of 65
The three versions of ApoE are very similar in structure, Wong explained: Compared with ApoE2, ApoE3 contains an amino acid substitution, causing the protein to have more positive charges
In their new research, Dr.
The researchers used genetically modified mice to simulate Alzheimer’s disease and produce human forms of ApoE4 and amyloid.
However, when the researchers used genetic technology to turn off a gene called NHE6 in brain cells, they found that the negative effects of ApoE4 were eliminated, and the protein was transported in the cell without obstacles
"Inhibition of NHE6 produces the same protective effect as ApoE2, and we hope that this effect can eventually be replicated by drugs," Ms.
The team plans to continue to study this mechanism and how to inhibit NHE6 in future studies
Current and previous UTSW researchers involved in this study include co-lead author Theresa Pohlkamp, now at Regeneron Pharmaceuticals, Xunde Xian, and now at Peking University, as well as Murat S.
National Institutes of Health (R37 HL063762, R01 NS093382, R01 NS108115, RF1 AG053391, and National Institute of Aging 1F31 AG067708-01), Darrell K Royal Research Foundation, BrightFocus Foundation (A20135245, A2016396S); Harrington Discovery Institute ; The Moments of Friends pilot synergy grant; and the Bluefield project for the treatment of FTD
Dr.
Journal Reference :
Theresa Pohlkamp, Xunde Xian, Connie H Wong, Murat S Durakoglugil, Gordon Chandler Werthmann, Takaomi C Saido, Bret M Evers, Charles L White, Jade Connor, Robert E Hammer, Joachim Herz.
